Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released March 16, 2018 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Texas is a whole lot more than cowboy boots and rodeos. Both are cherished parts of the state's vibrant culture, but to stop there is like not letting the bull out of the chute, because today's Texas has 99 active reported Pharmaceutical-Biotech capital and maintenance projects worth a yee-haw worthy $4 billion in total investment.
Click on image at right for the top 10 counties in Texas for Pharma-Biotech project activity.
How did Texas land on the life science industry radar? A variety of reasons, including sweet incentive deals by cities and a state that wants to be known as "Open for Business." Texas offers an almost unparalleled logistics platform, whether by land, rail or sea, and the infrastructure is in place to efficiently move virtually every kind of product from anywhere in the vast state.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer. The Houston area is slowly building on its commercial life-science potential. As home to the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings.
Adding to the mix of activity is the number of public institutions upping their investment in constructing research laboratories that not only train tomorrow's scientists, but also actively work on developing therapeutics that can eventually be turned into an income-producing drug product. Drug companies support these efforts for obvious reasons.
Some of the projects co-mingle with the state's more expected industries. Such is the case of BASF SE (Ludwigshafen, Germany) and the manufacturing campus it shares with Celanese Corporation (NYSE:CE) (Irving, Texas) in Bishop, Texas. BASF is putting the final touches on a $30 million expansion. The project added two 17,000-square-foot buildings to increase production of active pharmaceutical ingredients (APIs), including Ibuprofen DC 85, Sodium Ibuprofen di-Hydrate, 4-Hydroxyacetophenone, 2-Hydroxyacetophenone and Phenyl Acetate (current capacity approximately 8 million pounds per year). For more information, view Industrial Info's project report.
In Pearland, Lonza Group (Basel, Switzerland) decided to invest $150 million on a new plant to house viral and immunotherapy development and manufacturing. When completed later this year, the site will offer process development, quality-control laboratories and a fully segregated fill/finish suite, essentially doubling the company's current capacity for the production of viral gene and virally modified therapeutics. The facility's eight modular cleanrooms will allow for up to 2,000 L-scale production in single-use bioreactors, along with cleanrooms designed to meet the requirements for the manufacture of cell therapy products for use in both the U.S. and European markets. For more information, view Industrial Info's project report.
Following a delay, Allergan (Dublin, Ireland) is back in planning for a $200 million expansion of its plant in Waco. At the existing 400,000-square-foot facility, the project will add approximately 322,000 square feet (including a 221,000-square-foot first floor expansion and an approximately 87,000-square-foot mezzanine level expansion), along with added warehouse space. Upon completion, the company will have double the current production capacity of ophthalmic and dermatological gels, suspensions, solutions, ointments and other related pharmaceuticals (products include Restasis, Lumigan, Combigan, Refresh Plus, Refresh Tears and Latisse). For more information, view Industrial Info's project report.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
Click on image at right for the top 10 counties in Texas for Pharma-Biotech project activity.How did Texas land on the life science industry radar? A variety of reasons, including sweet incentive deals by cities and a state that wants to be known as "Open for Business." Texas offers an almost unparalleled logistics platform, whether by land, rail or sea, and the infrastructure is in place to efficiently move virtually every kind of product from anywhere in the vast state.
These projects top every city planner's list because of the typically high wages and future expansion prospects they offer. The Houston area is slowly building on its commercial life-science potential. As home to the world's top medical center, the area is a veritable brain trust when it comes to answering the medical needs of human beings.
Adding to the mix of activity is the number of public institutions upping their investment in constructing research laboratories that not only train tomorrow's scientists, but also actively work on developing therapeutics that can eventually be turned into an income-producing drug product. Drug companies support these efforts for obvious reasons.
Some of the projects co-mingle with the state's more expected industries. Such is the case of BASF SE (Ludwigshafen, Germany) and the manufacturing campus it shares with Celanese Corporation (NYSE:CE) (Irving, Texas) in Bishop, Texas. BASF is putting the final touches on a $30 million expansion. The project added two 17,000-square-foot buildings to increase production of active pharmaceutical ingredients (APIs), including Ibuprofen DC 85, Sodium Ibuprofen di-Hydrate, 4-Hydroxyacetophenone, 2-Hydroxyacetophenone and Phenyl Acetate (current capacity approximately 8 million pounds per year). For more information, view Industrial Info's project report.
In Pearland, Lonza Group (Basel, Switzerland) decided to invest $150 million on a new plant to house viral and immunotherapy development and manufacturing. When completed later this year, the site will offer process development, quality-control laboratories and a fully segregated fill/finish suite, essentially doubling the company's current capacity for the production of viral gene and virally modified therapeutics. The facility's eight modular cleanrooms will allow for up to 2,000 L-scale production in single-use bioreactors, along with cleanrooms designed to meet the requirements for the manufacture of cell therapy products for use in both the U.S. and European markets. For more information, view Industrial Info's project report.
Following a delay, Allergan (Dublin, Ireland) is back in planning for a $200 million expansion of its plant in Waco. At the existing 400,000-square-foot facility, the project will add approximately 322,000 square feet (including a 221,000-square-foot first floor expansion and an approximately 87,000-square-foot mezzanine level expansion), along with added warehouse space. Upon completion, the company will have double the current production capacity of ophthalmic and dermatological gels, suspensions, solutions, ointments and other related pharmaceuticals (products include Restasis, Lumigan, Combigan, Refresh Plus, Refresh Tears and Latisse). For more information, view Industrial Info's project report.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
